Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In 51 patients, for patient-based analysis, the sensitivity, specificity and accuracy of Ga-PSMA PET-CT in detecting lymphnodal metastases were 80, 90.3 and 86.3%, respectively, and for lesion-based analysis 69.2, 99.6 and 98.4%, respectively.
|
31714366 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, the present study aimed to evaluate the role of PSMA PET/CT in detecting nodal metastases in a large cohort of men and compare imaging results with the risk of lymph node involvement based on the Roach formula.
|
31302638 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) is a novel and promising imaging modality which aims to overcome the incapability of early identification of distant and regional metastases.
|
30929322 |
2020 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high prostate-specific membrane antigen expression in prostate cancer metastases makes it a promising approach for targeted radionuclide therapy of prostate cancer.
|
31162261 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) is a promising technique that outperformed conventional imaging in the detection of nodal and distant metastases in previous studies.
|
31802175 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Ga-PSMA PET/CT has become a well-established imaging modality to detect prostate cancer (PCa) metastases in biochemical recurrence.
|
31306199 |
2020 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ga-PSMA expression in fibrous dysplasia should not automatically be equated with malignant transformation or confused with prostate cancer metastases.
|
31058693 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with newly-diagnosed M1a/b prostate cancer (PSMA PET/CT staging is permitted) and 1-5 radiographically visible metastases (excluding pelvic lymph nodes) are undergoing local treatment with radical prostatectomy, limited duration systemic therapy for a total of six months (leuprolide, abiraterone acetate with prednisone, and apalutamide), metastasis-directed stereotactic body radiotherapy (SBRT), and post-operative fractionated radiotherapy if pT ≥ 3a, N1, or positive margins are present.
|
30935383 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Alternatively, fluorine-18 (<sup>18</sup>F)-labelled PSMA tracers are available, such as <sup>18</sup>F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases.
|
31230088 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
At multivariate analysis, age, sex, histotype, vascular invasion, T and N parameters, and PSMA positivity were significant predictors of distant metastases.The AUC was 0.92.
|
31617002 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
68Ga-PSMA PET/CT Urachus Metastases in Recurrent Prostate Cancer With Very Low PSA Level.
|
30540597 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Results:</b> The projected dosimetry for <sup>90</sup>Y-PSMA-617 estimated a mean kidney dose of 3.47 ± 1.40 Gy/GBq, red marrow dose of 0.11 ± 0.04 Gy/GBq, and salivary gland dose of 5.57 ± 1.34 Gy/GBq; randomly chosen metastases were approximated with 22.8 ± 16.10 Gy/GBq.
|
30389816 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Methods:</b> PSMA protein expression in tissue samples from 50 ACCs, 90 ACAs (including 20 from patients who presented with Cushing's syndrome, 20 aldosterone-producing adenomas and 50 non-functional tumors) and 10 tissues that were metastases from other primary sites was assessed by immunohistochemistry.
|
31040822 |
2019 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PATIENT SUMMARY: In selected patients with prostate-specific antigen (PSA) increase during androgen deprivation, metastases were detected with prostate-specific membrane antigen positron emission tomography imaging.
|
30578119 |
2019 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We further evaluated SPARTAN patients stratified by risk factors for PSMA-PET-detected M1 disease.
|
31511295 |
2019 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PSMA PET-CT showed findings compatible with local disease in 47 patients (66.2%), lymph node metastases in 10 patients (14.1%) and distant metastases in 14 patients (19.7%).
|
31829288 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT is a valuable tool for the detection of PC local recurrence or extraprostatic metastases following rising PSA levels after primary definitive therapy and should be incorporated during routine work-up.
|
29935970 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Regional and template-based correlations between the presence of LN metastases on histopathology and whole-body PSMA-11 PET/CT(MRI) results were evaluated.
|
31254037 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A significant (p ≤ 0.05) correlation between SUV<sub>max</sub> in PSMA-positive liver metastases and both size (ρ<sub>Spearman</sub> = 0.57) of metastases and PSA serum level (ρ<sub>Spearman</sub> = 0.60) was found.
|
31186052 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared to bone scan, PSMA-PET is more sensitive and specific to detect metastases but the therapeutic consequences of PSMA-PET results in the setting of CRPC remain unclear.
|
30030659 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our purpose was to assess whether the addition of data from multiparametric pelvic MRI (mpMR) and whole-body MRI (wbMR) to the interpretation of <sup>18</sup>F-fluoromethylcholine (<sup>18</sup>F-FCH) or <sup>68</sup>Ga-HBED-CC PSMA-11 (<sup>68</sup>Ga-PSMA) PET/CT (=PET) improves the detection of local tumor recurrence or of nodal and distant metastases in patients after radical prostatectomy with biochemical failure.
|
30902875 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
All the patients had undergone Ga-68 PSMA PET/CT scanning before Lu-177 PSMA therapy, which revealed multiple metastases.
|
31602963 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CT.
|
31058686 |
2019 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although it is generally accepted that higher PSA values indicate higher disease burden, few data are available on the relation between PSA levels and number of detected metastases on PSMA PET/CT.
|
31274553 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, <sup>64</sup> Cu-PSMA-617-PET demonstrated to be feasible for imaging prostate cancer for both the primary tumor site and metastases.
|
31042811 |
2019 |